- 1 Article [Working Title]: A multi-ancestry genome-wide association study identifies
- 2 novel candidate loci in the RARB gene associated with hypertensive disorders of
- 3 pregnancy
- 4 Short Title: Multi-ancestry GWAS of hypertension in pregnancy
- Jasmine A. Mack^{1,2}, Adam Burkholder¹, Farida S. Akhtari¹, John S. House¹, Ulla
- 6 Sovio², Gordon C.S. Smith², Charles P. Schmitt¹, David C.Fargo¹, Janet E. Hall¹, Alison
- 7 A. Motsinger-Reif¹
- National Institute of Environmental Health Sciences, Research Triangle Park, NC
- 9 27709, USA
- ² University of Cambridge, Department of Obstetrics and Gynaecology, Cambridge, UK,
- 11 CB2 0SW

15

16

18

19

20

21

22

23

24

25

26

27

28

29

- 13 Corresponding author: Alison Motsinger-Reif
- 14 alison.motsinger-reif@nih.gov
- 17 Word count: 7917

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51 52

53

54

55

56 57

58

59

60

61

62

63

64

2

Abstract Background Genetic factors related to pregnancy-related traits are understudied, especially among ancestrally diverse cohorts. This study assessed maternal contributions to hypertensive disorders of pregnancy (HDP) in multi-ancestry cohorts. **Methods** We performed a genome-wide association study of HDP using data from the Personalized Environment and Genes Study (PEGS) cohort (USA) with validation in the UK Biobank (UKBB). We performed gene-level and gene-set analyses and tested the association of polygenic scores (PGS) for systolic blood pressure (SBP), preeclampsia (PE), and gestational hypertension (GH). Results We identified two novel maternal genome-wide significant associations with HDP. The lead independent variants were rs114954125 on chromosome 2 (near LRP1B: OR (95% CI): 3.03 (2.05, 4.49); P=3.19 x 10⁻⁸) and rs61176331 on chromosome 3 (near RARB; OR (95% CI): 3.09 (2.11, 4.53); $P=7.97\times10^{-9}$). We validated rs61176331 in the UKBB ($P=3.73 \times 10^{-2}$). When aggregating SNPs by genes, RARB ($P=1.36 \times 10^{-3}$) and RN7SL283P (P=2.56 x 10⁻²) were associated with HDP. Inflammatory and immunological biological pathways were most strongly related to HDP-associated genes. While all blood pressure and HDP-related PGS were significantly associated with HDP in PEGS, the SBP PGS was a stronger predictor of HDP (area under the curve (AUC): 0.57; R²=0.7%) compared to the PE PGS (AUC: 0.53; R²=0.2%). Conclusion Our study is the first to identify and validate maternal genetic variants near RARB associated with HDP. The findings demonstrate the power of multi-ancestry studies for genetic discovery and highlight the relationship between immune response and HDP and the utility of PGS for risk prediction. ClinicalTrials.gov Identifier for PEGS: NCT00341237

Non-standard Abbreviations and Acronyms

AFR	African ancestry
AMR	Admixed American ancestry
EAF	Effect allele frequency
EAS	East Asian ancestry
EUR	European ancestry
GH	Gestational hypertension
GWAS	Genome-wide association study
HDP	Hypertensive disorders of pregnancy
KEGG	Kyoto Encyclopedia of Genes and Genomes
MAC	Minor allele count
MIM	Mendelian Inheritance in Man
PCA	Principal components analysis
PE	Preeclampsia
PEGS	Personalized Environment and Genes Study
PGS	Polygenic score
SAS	South Asian ancestry
SNP	Single nucleotide polymorphism
SNV	Single nucleotide variant
UKBB	UK Biobank

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

4

placental perfusion causing systemic vascular endothelial dysfunction through the

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

release of antiangiogenic factors from the placenta^{11,12}. Placental hypoperfusion is thought to be caused by failure of transformation of uterine spiral arteries into lowresistance conduits, which is a normal feature of invasion by extravillous cytotrophoblast^{13,14}. Failure of spiral artery transformation has been linked to fetal growth restriction, miscarriage, and PE¹⁴. Moreover, placental factors can interact with maternal genetics, epigenetics, and environmental factors to influence the response to placental dysfunction¹⁵. Maternal immune system changes are involved in the development and pathogenesis of PE¹⁶⁻²², but the mechanisms are incompletely understood. Early genetic studies of HDP have been predominantly focused on individuals of European ancestry^{23,24}. In research in large cohorts with genetic data, participants from underrepresented racial/ethnic groups are consistently excluded from published analyses due to small sample sizes and the use of sparse methods to account for population structure^{25–27}. Prior genome-wide association studies (GWAS) of PE have revealed strong signals near the FLT1 gene (MIM:165070) based on a meta-analysis of fetal genotypes from five cohorts, of which all participants were of European ancestry: Genetics of Pre-Eclampsia (GOPEC), Avon Longitudinal Study of Parents and Children (ALSPAC), deCODE, Norwegian Mother and Child (MoBa), and Finnish Genetics of Pre-eclampsia

Consortium (FINNPEC)²⁴. The largest maternal genome-wide multi-ancestry meta-

analysis of PE and GH was conducted in cohorts comprising FinnGen, Estonian

biobank, Genes and Health, Michigan Genomics Initiative, Mass General Brigham Biobank, Biobank Japan, BioMe Biobank, InterPregGen Consortium, Trøndelag Health Study (HUNT), UKBB, Penn Medicine Biobank, and Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-Be (nuMoM2b)²⁸. Among 31,091 HDP cases assessed in the meta-analysis, 83% were of European ancestry. Multi-ancestry meta-analyses have been conducted in diverse cohorts such as the Pan UK Biobank (UKBB), but the control groups of the GWAS also included female UKBB participants who have never been pregnant²⁹.

To increase diversity and support the representation of non-European populations in genomics research, GWAS that include minority racial and ethnic groups can be conducted in currently available data from diverse cohorts. The results can be stratified by ancestry, and meta-analyses can jointly model effects in a multi-ancestry analysis. Building upon previous multi-ancestry genetic studies, we conducted multi-ancestry GWAS in whole-genome sequencing (WGS) data from a discovery cohort from the North Carolina-based Personalized Environment and Genes Study (PEGS) using a case-control study design. The joint modeling exhibited improved power for genetic discovery, enabling the first discovery of a maternal genetic association near the retinoic acid receptor (*RARB*) gene (MIM: 180220) with HDP. We validated this association in the UKBB and a meta-analysis in PEGS and the UKBB. In downstream analyses, we performed gene-level analysis and gene-set analyses to elucidate the biological mechanisms involved in HDP. Further, in the PEGS dataset, we assessed the predictive

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

7

criteria include women who self-report being pregnant, a small number of participants

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

8

used for the analyses from PEGS Data Freeze version 2.0 created in August 2021. The

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

9

cases and controls separately for each cohort and harmonized the case-control sets as

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

10

by Fisher's exact test to assess associations among covariates and performed t-tests

for continuous variables. For variables without normal distribution, such as BMI, we used the Mann-Whitney U test.

Genome-wide Association Study for Common Variants

We conducted GWAS (MAF>=0.03) using multivariable logistic regression to model the odds of HDP, assuming an additive allelic genetic model. We adjusted for the top 10 genetic principal components, self-reported race/ethnicity, age and BMI at enrollment, and gravidity. We used PLINK2.0³⁵ for all GWAS with Firth-corrected logistic regression modeling to account for case-control imbalance³⁶. Because information on gravidity was available for few UKBB participants, we excluded this covariate in the UKBB analyses. We included genotyping batch as a covariate in the UKBB analyses given that two types of arrays were used in genotyping with 106 batches²⁵. We used a threshold of $P < 5 \times 10^{-8}$ for genome-wide significance and $P < 1 \times 10^{-6}$ for suggestive significance.

In addition to the main outcome of HDP, we performed GWAS for three other phenotypes in the PEGS discovery cohort (PE, GH without PE, and GH and/or PE) for all individuals and separately for the AFR and EUR similarity groups. We adjusted for within-group variation using the top 10 principal components, age and BMI at enrollment, and gravidity. The AMR, EAS, and SAS similarity groups had insufficient numbers of participants to perform stratified analyses (**Table 1**).

To validate our findings, we filtered GWAS summary statistics from the PEGS multiancestry analysis to include only variants with suggestive association ($P < 1 \times 10^{-6}$). We assessed these variants in the UKBB using harmonized cases and controls. We used GCTA-COJO for conditional and joint analyses to identify independently associated loci³⁷. We used METAL to perform inverse variance-weighted meta-analyses for variants with suggestive association in PEGS and UKBB³⁸.

Gene-based Association Analysis and Gene-set Analysis

To increase statistical power for discovery, we used MAGMA to perform gene-set association analysis, adjusting for the top 10 genetic principal components, self-reported race/ethnicity, age and BMI at enrollment, and gravidity. We used Ensembl annotation on GRCh38 to map the SNVs from the GWAS to 31,427 genes³⁹. We utilized the results from the gene-level analysis to perform gene-set analysis in MAGMA^{40,41}. We used the Kyoto Encyclopedia of Genes and Genomes (KEGG) to define gene sets by biological pathways and conditions^{42,43}. To control the false discovery rate (FDR), we used the Benjamini-Hochberg method to adjust P values from the statistical analyses for multiple comparisons. We define statistical significance by an adjusted P value of 0.05 and suggestive FDR-corrected significance by an adjusted P value of 0.10.

Application of Polygenic Scores

To assess the predictive value of SBP, PE, and GH for HDP in PEGS, we applied an SBP PGS derived from the UKBB female sub-cohort in Kauko et al.⁴⁴ and separate scores for SBP, PE, and GH from meta-analyses in Honigberg et al.²⁸. We separately computed the four PGS in the PEGS pregnancy (n = 1,771) and female sub-cohorts (n

between HDP risk and the standardized PGS, adjusting for the top ten genetic principal components, self-reported race/ethnicity, age and BMI at enrollment, and gravidity. For further validation, we tested the association of each PGS with essential hypertension in the PEGS female sub-cohort, adjusting for the same covariates except gravidity. Additionally, we performed stratified analyses for the AFR and EUR genetic similarity groups. For each PGS, we report odds ratios per standard deviation with a 95% CI. We calculated the AUC for each model using the pROC package in R to assess discriminative ability. All PGS analyses were performed in R 4.3.1 with a significance threshold of 0.05.

The Major Resources Table in the **Supplemental Materials** provides details on data and code availability.

Results

In the PEGS cohort, participants with HDP (11.4% of the study sample) were younger, had a higher BMI at enrollment, and had more pregnancies compared to participants in the control group (*P*<0.001; **Table 1**). Among HDP cases, 4.5% experienced recurrent diagnoses of PE, and 18.8% experienced GH during two or more pregnancies. Race/ethnicity distribution, education level, and income were similar for the case and

control groups (**Table 1**). In the UKBB cohort, race/ethnicity, predominant genetic similarity group, and education level were similar for cases and controls (**Table S2**). Similar to PEGS, UKBB participants with HDP were younger (*P*=0.024) and had a higher BMI at recruitment (*P*<0.001) compared to controls.

Novel Maternal Loci Identified on RARB

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

In the PEGS GWAS, 11 variants in two loci met genome-wide significance (Figure 1A; **Table S3**) for HDP. An association was found for a significant novel candidate region in the maternal genome (202 cases and 1.569 controls) consisting of intergenic variants near the low-density lipoprotein (LDL) receptor-related protein 1B (LRP1B; MIM:608766) gene on chromosome 2 (Figure 1B). A stronger signal was observed for a region identified as intronic to the RARB gene (MIM:180220) on chromosome 3 (Figure 1C). The lead variant was rs61176331, with an OR of 3.09 for HDP (EAF: 0.048; 95% confidence interval (95% CI): (2.11, 4.53); *P*=7.97 x 10⁻⁹). The second most significant variant was rs114954125, with an OR of 3.03 (EAF: 0.051; 95% CI: (2.05, 4.49); $P=3.19 \times 10^{-8}$) (**Table 2**). A genomic inflation factor of 1.02 indicated sufficient adjustment for population stratification (Figure S2A). Conditional and joint analyses confirmed that rs61176331(P_{ioint} =9.56 x 10⁻⁹) and rs114954125 (P_{oint} =3.79 x 10⁻⁸) are independent loci (Table 2). In results stratified by genetic similarity group, these loci had larger effect sizes although the P values were attenuated. rs61176331 had an OR of 6.98 and 2.37 for the AFR and EUR genetic similarity groups, respectively (Table 2; Figure S2B). rs114954125 had a similar effect size as the multi-ancestry GWAS for the EUR genetic similarity group, but this variant did not reach the quality control threshold

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

in the AFR genetic similarity group. We validated rs61176331 in the UKBB analysis (OR: 1.29; 95% CI: (1.02, 1.65); $P=3.73 \times 10^{-2}$) (**Figure S2B**). In the meta-analysis including PEGS and UKBB, strong associations remained for the candidate region near RARB (Table 2; Table S3). In a sensitivity analysis with three HDP subtypes as the outcome (PE, GH only, and GH and/or PE; Figure S3), there was distinct attenuation of signals in the multi-ancestry HDP GWAS with PE as the outcome (21 cases) (Figure S3A). In this GWAS, the candidate signal on RARB was attenuated below the genome-wide significance threshold while rs114954125 on chromosome 2 remained significant. (Figure S3E). Significant Gene-wide Associations for RARB Figure 2 is a gene-based Manhattan plot. Two gene signals met the FDR-corrected significance threshold—RARB (P=1.36 x 10⁻³) and RN7SL283P (P=2.56 x 10⁻³). Among the top 15 most significant genes, there were strong peaks on chromosome 6 (HLA-DRB5, BTNL2, RNU1-61P) and chromosome 17 (LRRC59, EME1, ACSF2; Table S4) although these associations did not reach gene-wide significance. Immune-related Pathways Linked to HDP Among the ten most significant KEGG gene sets associated with HDP were the pentose phosphate pathway and the hedgehog signaling pathway (Figure 3). Gene-set analyses revealed additional immune-related diseases and processes related to HDP-associated genes (Table S5), but these sets, which included autoimmune thyroid disease, graft-

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

versus-host disease, adipocytokine signaling pathway, and allograft rejection (uncorrected P<0.05), did not meet the FDR-corrected significance threshold. Polygenic Score for Systolic Blood Pressure is Associated with HDP We tested the association of HDP with PGS for SBP, PE, GH with HDP, and essential hypertension in the PEGS female sub-cohort. **Table S6** shows the number of variants missing in the PEGS cohort for each PGS. In the overall model, all four PGS were significantly associated with HDP (P<0.05). The AUC (0.57; 95% CI: (0.52-0.61); Figure 4; Figure S5) and pseudo-R² (0.7%; Table S7) were the highest for the SBP PGS [1] based on the UKBB. One standard deviation increase in the SBP PGS [1] was associated with a 2.09-fold increase in HDP odds (95% CI: 1.40, 3.13). GH-PGS had the highest OR for HDP (Figure 4). Figure S6 shows HDP prevalence by percentile for each PGS. When the results were stratified by genetic similarity group, the four PGS were not significantly associated with HDP in the AFR genetic similarity group, but there were similar effect sizes for the overall models and for the EUR genetic similarity group (Figure 4). For essential hypertension, the two SBP PGS were strongly associated with HDP in both the overall and stratified analyses (Figure S4). The pseudo-R² for SBP PGS [2] was the highest at 5.6% (**Table S7**). The receiver operator characteristic curves indicate that SBP PGS [2] is the most predictive of essential hypertension in PEGS (Figure S7), evidenced by the clear linear trend in the percentile plot (**Figure S8**).

Discussion

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

Our GWAS is the first to identify and validate genetic variants that are significantly associated with HDP in the maternal genome in *RARB* on chromosome 3. By leveraging a multi-ancestry study design, we increased statistical power for genetic discovery, which enabled us to confirm our findings in the clinically phenotyped UKBB cohort.

The two genome-wide significant loci in PEGS were also significantly associated with HDP in the gene-level analysis, where RARB and RN7SL283P were the top two genes. Retinoic acid receptors are essential for healthy placental and fetal development. The receptor binds retinoic acid, which is the biologically active form of vitamin A that facilitates cellular signaling in embryonic morphogenesis, cell proliferation, differentiation, and apoptosis^{45–47}. Maternal retinol is transferred across the placenta to embryos⁴⁷. All-trans-retinoic acid plays a significant role in maintaining immune balance in some tissues and is linked to the etiology of PE, where greater dysregulation in retinoic acid levels in the decidua (maternal endometrium) is observed in PE cases compared to those with a normal pregnancy⁴⁸. A link has been suggested between decidualization and the anti-angiogenic protein soluble fms-like tyrosine kinase-1 (sFLT1), with retinoic acid directly reducing sFLT1 production in the decidua, which affects early vascular development⁴⁸. Furthermore, in GWAS in a Peruvian cohort focused on maternal and offspring genetic effects on PE, rs4241542, a variant that is 80 kb from the lead variant rs61176331, was associated with proteinuria in offspring $(P=8.48 \times 10^{-6})^{49}$, further supporting the biological validity of this region in RARB for

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

HDP. Future research is needed to investigate the interaction at the maternal-fetal interface, including the influence of gene-gene interaction in placental pathophysiology. While the variant near *LRP1B* was not validated in UKBB, rs114954125 is near RN7SL283P, which is a pseudogene. LRP1B belongs to the LDL receptor family and is a tumor suppressor gene⁵⁰. In a previous candidate SNP study, the T-allele variant in LRP1B, rs35821928, was associated with increased maternal height and decreased maternal weight⁵¹. While the MAGMA gene-set analysis did not yield pathways that met the stringent FDRcorrected significance threshold, the top ten most significant gene sets provide intriguing insights into the probable molecular mechanisms of HDP. The pentose phosphate pathway is among these notable gene sets. This metabolic pathway is involved in cellular redox homeostasis, which is related to oxidative stress as a factor in HDP^{11,12}. The identification of immune-response pathways and conditions such as autoimmune thyroid disease, graft-versus-host disease, and allograft rejection points to an immunological dysregulation component of HDP. This is consistent with a growing body of research focused on the immunological basis of HDP^{52,19,22,48}. The gene-level analysis revealed a strong peak of genes at chromosome 6 that did not meet the gene-wide significance threshold. *HLA-DRB5* and *BTNL2* belong to the human major histocompatibility (HLA) complex, where they are involved in the generation of an

immune response. Additionally, the adipocytokine signaling pathway connects to

signaling molecules originating from adipose tissue, which has been linked to various aspects of cardiovascular health. This could indicate adipose tissue malfunction plays a role in HDP and other cardiometabolic disorders of pregnancy such as gestational diabetes⁵³. These suggestive findings related to immune response, inflammation, and metabolic dysfunction call for further analysis and interpretation in large pregnancy cohorts.

The differing patterns of suggestive associations in the GWAS of the composite HDP outcome, GH, and PE in PEGS may indicate differences in etiology (**Figure S3**). The heterogeneous nature of HDP has led to the understanding that there are several distinct PE subtypes. A two-stage placental model related to the development of PE^{19,54} demonstrated that an early-onset, more severe subtype may be associated with underlying genetic or environmental factors that result in abnormal placentation. In contrast, a later-onset, less severe subtype may be a consequence of factors such as obesity, diabetes, cardiovascular disorders, or multi-fetal pregnancy¹. Further, risk factors for GH and PE vary⁵⁵, supporting evidence for differing etiology across the collection of hypertensive disorders. However, a holistic assessment of HDP that combined PE with other maternal hypertensive disorders as a phenotype for GWAS yielded novel, overlapping risk loci identified in models of PE only and PE or other HDP⁵⁶.

Considering polygenic prediction, using a blood pressure PGS to predict HDP has been found to be more effective than using a PE PGS for women who are non-hypertensive

before pregnancy⁵⁷. In this study, we assessed the predictive utility of four PGS in the context of HDP and essential hypertension. While these scores were developed in the White British sub-cohort of UKBB^{28,44}, our results demonstrate that an SBP PGS is a strong predictor of HDP. In the stratified results, none of the scores exhibited predictive value for HDP for the AFR genetic similarity group, and only the SBP scores were significantly associated with essential hypertension. These findings highlight the need for customizing PGS development to be inclusive of varying genetic similarity backgrounds to improve the accuracy of HDP risk assessment, as the study's effectiveness in predicting HDP using a PE PGS or GH PGS does not apply to all populations. Furthermore, while the SBP PGS showed promise for HDP prediction and prevention, it is worth investigating how these genetic scores could be combined with other clinical and environmental factors to develop a more holistic approach to HDP prediction and prevention.

This study has several limitations. First, a composite outcome like HDP can obscure disparate etiologies, for example, between PE and GH. Because of the limited sample size, we grouped the heterogeneous conditions that comprise HDP to increase power to detect genetic variant associations. Second, the results are based on data from a particular time point for each participant. The lack of longitudinal data does not allow us to account for the continuum of risk due to factors such as maternal age and gestational age at the onset of HDP. Further, the study design does not consider the recurrence of complications in subsequent pregnancies. Third, the outcomes are dichotomized due to the nature of the questionnaires completed, which may result in the oversimplification of

adverse pregnancy outcomes. Fourth, misclassification bias may be present, since participants who enrolled in PEGS before a pregnancy complication occurred were included in the control group. Fourth, there is a lack of harmonization of phenotypes between study cohorts. While PEGS data are limited, the UKBB uses a wide variety of diagnosis codes for phenotyping, and thus not all pregnancy-related adverse outcomes were excluded from the control group.

Perspectives (max 250 words - Conclusion)

Variants near *RARB* were significantly associated with HDP in a multi-ancestry cohort. We validated this association in a clinically phenotyped cohort. In gene-set analyses, probable mechanisms associated with HDP included inflammatory and immunological pathways. These findings are supported by recent research focused on the relationship between retinoic acid dysregulation and PE. In-depth functional genomics investigations can elucidate the molecular pathways by which genetic variations near *RARB* contribute to the etiology of HDP, such as the influence of these variants on *RARB* expression, epigenetic alterations, and downstream signaling pathways within the placenta and maternal vascular system. The study demonstrates the strong predictive value of SBP PGS for HDP, but further work should investigate approaches to improve the accuracy and inclusivity of risk assessment for HDP.

HDP is a complex and challenging area of obstetrics, with a significant, disproportionate impact on maternal and fetal health across populations. While we focus on the genetic contribution to HDP, examining the role of social determinants of health is also

important, in part because environmental factors can influence genetic risk and the development of HDP. Addressing social, lifestyle, and genetic factors is imperative to reduce the burden of HDP and improve maternal and fetal outcomes. Further research in large, diverse pregnancy cohorts is needed to fully understand the underlying mechanisms and develop effective preventative and therapeutic strategies.

Novelty and Relevance (max 100 words)

What is new?

- Genetic studies of hypertensive disorders of pregnancy (HDP) have predominantly focused on individuals of European ancestry.
- Our multi-ancestry genome-wide association study is the first to identify and validate genetic variants that are significantly associated with HDP in the maternal genome in the RARB gene.

What is relevant?

We identified two novel genome-wide significant associations with HDP in the
maternal genome, namely rs114954125 on chromosome 2 and rs61176331 on
chromosome 3. The variant rs61176331 was validated in the UK Biobank. Geneset analyses revealed a suggestive association between HDP and
inflammatory/immunological pathways such as the pentose phosphate pathway
and autoimmune thyroid disease.

Clinical/Pathophysiological Implications?

None

532

533

534

Supplemental Material

- 537 Supplemental Methods
- 538 Tables S1–S7

536

541

542

- 539 Figures S1-S8
- 540 References #58-#90

References

- 1. Hutcheon JA, Lisonkova S, Joseph KS. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. *Best Pract. Res. Clin. Obstet. Gynaecol.* 2011;25:391–403.
- Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. *Lancet Lond. Engl.* 2006;367:1066–1074.
- 3. Sole KB, Staff AC, Räisänen S, Laine K. Substantial decrease in preeclampsia prevalence and risk over two decades: A population-based study of 1,153,227 deliveries in Norway. *Pregnancy Hypertens*. 2022;28:21–27.
- Wang W, Xie X, Yuan T, Wang Y, Zhao F, Zhou Z, Zhang H. Epidemiological trends of maternal hypertensive disorders of pregnancy at the global, regional, and national levels: a population-based study. *BMC Pregnancy Childbirth*.
 2021;21:364.
- 5. Ghulmiyyah L, Sibai B. Maternal mortality from preeclampsia/eclampsia. *Semin. Perinatol.* 2012;36:56–59.
- 6. GBD 2015 Maternal Mortality Collaborators. Global, regional, and national levels of maternal mortality, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet*. 2016;388:1775–1812.
- 7. Fasanya HO, Hsiao CJ, Armstrong-Sylvester KR, Beal SG. A critical review on the use of race in understanding racial disparities in preeclampsia. *J. Appl. Lab. Med.* 2021;6:247–256.
- 8. Johnson JD, Louis JM. Does race or ethnicity play a role in the origin, pathophysiology, and outcomes of preeclampsia? An expert review of the literature. *Am. J. Obstet. Gynecol.* 2022;226:S876–S885.

- 9. Bartsch E, Medcalf KE, Park AL, Ray JG. Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. *BMJ*. 2016;353:i1753.
- 570 10. Braunthal S, Brateanu A. Hypertension in pregnancy: Pathophysiology and treatment. *SAGE Open Med.* 2019;7:2050312119843700.
- 572 11. Gilbert JS, Ryan MJ, LaMarca BB, Sedeek M, Murphy SR, Granger JP.
 573 Pathophysiology of hypertension during preeclampsia: linking placental ischemia
 574 with endothelial dysfunction. *Am. J. Physiol.-Heart Circ. Physiol.* 2008;294:H541–
 575 H550.
- LaMarca B. Endothelial dysfunction. An important mediator in the pathophysiology of hypertension during preeclampsia. *Minerva Ginecol.* 2012;64:309–320.
- 578 13. Braunthal S, Brateanu A. Hypertension in pregnancy: pathophysiology and treatment. *SAGE Open Med.* 2019;7:2050312119843700.
- 580 14. Lyall F, Bulmer JN, Kelly H, Duffie E, Robson SC. Human trophoblast invasion and spiral artery transformation. *Am. J. Pathol.* 1999;154:1105–1114.
- 582 15. Roberts JM, Rich-Edwards JW, McElrath TF, Garmire L, Myatt L, Global 583 Pregnancy Collaboration. Subtypes of preeclampsia: recognition and determining 584 clinical usefulness. *Hypertension*. 2021;77:1430–1441.
- 16. Lu H-Q, Hu R. The role of immunity in the pathogenesis and development of preeclampsia. *Scand. J. Immunol.* 2019;90:e12756.
- 587 17. Staff AC, Fjeldstad HE, Fosheim IK, Moe K, Turowski G, Johnsen GM, Alnaes-588 Katjavivi P, Sugulle M. Failure of physiological transformation and spiral artery 589 atherosis: their roles in preeclampsia. *Am. J. Obstet. Gynecol.* 2022;226:S895– 590 S906.
- Harmon AC, Cornelius DC, Amaral LM, Faulkner JL, Cunningham MW Jr, Wallace K, LaMarca B. The role of inflammation in the pathology of preeclampsia. *Clin. Sci.* 2016;130:409–419.
- 19. LaMarca B. The role of immune activation in contributing to vascular dysfunction and the pathophysiology of hypertension during preeclampsia. *Minerva Ginecol.* 2010;62:105–120.
- 597 20. Aneman I, Pienaar D, Suvakov S, Simic TP, Garovic VD, McClements L.
 598 Mechanisms of key innate immune cells in early- and late-onset preeclampsia.
 599 *Front. Immunol.* 2020;11:1864.
- 500 21. Smith SD, Dunk CE, Aplin JD, Harris LK, Jones RL. Evidence for immune cell involvement in decidual spiral arteriole remodeling in early human pregnancy. *Am. J. Pathol.* 2009;174:1959–1971.

- LaMarca B, Cornelius D, Wallace K. Elucidating immune mechanisms causing hypertension during pregnancy. *Physiology*. 2013;28:225–233.
- Gray KJ, Kovacheva VP, Mirzakhani H, Bjonnes AC, Almoguera B, DeWan AT, Triche EW, Saftlas AF, Hoh J, Bodian DL, et al. Gene-centric analysis of preeclampsia identifies maternal association at PLEKHG1. *Hypertension*. 2018;72:408–416.
- McGinnis R, Steinthorsdottir V, Williams NO, Thorleifsson G, Shooter S,
 Hjartardottir S, Bumpstead S, Stefansdottir L, Hildyard L, Sigurdsson JK, et al.
 Variants in the fetal genome near FLT1 are associated with risk of preeclampsia.
 Nat. Genet. 2017;49:1255–1260.
- Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A,
 Vukcevic D, Delaneau O, O'Connell J, et al. The UK Biobank resource with deep
 phenotyping and genomic data. *Nature*. 2018;562:203–209.
- 616 26. Mills MC, Rahal C. A scientometric review of genome-wide association studies. 617 Commun. Biol. 2019;2:1–11.
- Peterson RE, Kuchenbaecker K, Walters RK, Chen C-Y, Popejoy AB, Periyasamy S, Lam M, Iyegbe C, Strawbridge RJ, Brick L, et al. Genome-wide association studies in ancestrally diverse populations: opportunities, methods, pitfalls, and recommendations. *Cell.* 2019;179:589–603.
- Honigberg MC, Truong B, Khan RR, Xiao B, Bhatta L, Vy HMT, Guerrero RF, Schuermans A, Selvaraj MS, Patel AP, et al. Polygenic prediction of preeclampsia and gestational hypertension. *Nat. Med.* 2023;29:1540–1549.
- 29. Pan UKBB | Pan UKBB [Internet]. [cited 2021 Mar 30]; Available from:
 https://pan.ukbb.broadinstitute.org/
- National Institute of Environmental Health Sciences (NIEHS). Personalized
 Environment and Genes Study [Internet]. clinicaltrials.gov; 2022 [cited 2022 Sep
 Available from: https://clinicaltrials.gov/ct2/show/NCT00341237
- Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen W-M. Robust relationship inference in genome-wide association studies. *Bioinformatics*. 2010;26:2867–2873.
- 633 32. Maples BK, Gravel S, Kenny EE, Bustamante CD. RFMix: a discriminative modeling approach for rapid and robust local-ancestry inference. *Am. J. Hum. Genet.* 2013;93:278–288.
- Diaz-Papkovich A, Anderson-Trocmé L, Ben-Eghan C, Gravel S. UMAP reveals
 cryptic population structure and phenotype heterogeneity in large genomic
 cohorts. *PLOS Genet*. 2019;15:e1008432.

- 34. : Return 2442 [Internet]. [cited 2023 Jul 19]; Available from: https://biobank.ndph.ox.ac.uk/ukb/dset.cgi?id=2442
- Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets.
 GigaScience [Internet]. 2015 [cited 2021 Aug 30];4. Available from: https://doi.org/10.1186/s13742-015-0047-8
- 645 36. FIRTH D. Bias reduction of maximum likelihood estimates. *Biometrika*. 1993;80:27–38.
- Yang J, Ferreira T, Morris AP, Medland SE, Genetic Investigation of
 ANthropometric Traits (GIANT) Consortium, DIAbetes Genetics Replication And
 Meta-analysis (DIAGRAM) Consortium, Madden PAF, Heath AC, Martin NG,
 Montgomery GW, et al. Conditional and joint multiple-SNP analysis of GWAS
 summary statistics identifies additional variants influencing complex traits. *Nat.* Genet. 2012;44:369–375, S1-3.
- Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics*. 2010;26:2190–2191.
- Aken BL, Ayling S, Barrell D, Clarke L, Curwen V, Fairley S, Fernandez Banet J, Billis K, García Girón C, Hourlier T, et al. The Ensembl gene annotation system. *Database J. Biol. Databases Curation*. 2016;2016:baw093.
- de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS data. *PLoS Comput. Biol.* 2015;11:e1004219.
- Zhang S. A simplified protocol for performing MAGMA/H-MAGMA gene set
 analysis utilizing high-performance computing environments. STAR Protoc.
 2022;3:101083.
- 42. Kanehisa M, Goto S. KEGG: Kyoto Encyclopedia of Genes and Genomes.
 Nucleic Acids Res. 2000;28:27–30.
- Kanehisa M, Furumichi M, Sato Y, Ishiguro-Watanabe M, Tanabe M. KEGG: integrating viruses and cellular organisms. *Nucleic Acids Res.* 2021;49:D545–D551.
- 668 44. Kauko A, Aittokallio J, Vaura F, Ji H, Ebinger JE, Niiranen T, Cheng S. Sex 669 differences in genetic risk for hypertension. *Hypertension*. 2021;78:1153–1155.
- Huebner H, Hartner A, Rascher W, Strick RR, Kehl S, Heindl F, Wachter DL,
 Beckmann MW, Fahlbusch FB, Ruebner M. Expression and regulation of retinoic
 acid receptor responders in the human placenta. *Reprod. Sci.* 2018;25:1357–
 1370.

- 674 46. RARB retinoic acid receptor beta [Homo sapiens (human)] Gene NCBI [Internet]. [cited 2022 Sep 24];Available from:
 676 https://www.ncbi.nlm.nih.gov/gene/5915#summary
- 677 47. Rhinn M, Dollé P. Retinoic acid signalling during development. *Development*. 2012;139:843–858.
- 679 48. Rajakumar A, Kane MA, Yu J, Taylor RN, Sidell N. Aberrant retinoic acid 680 production in the decidua: Implications for pre-eclampsia. *J. Obstet. Gynaecol.* 681 *Res.* 2020;46:1007–1016.
- Nieves-Colón MA, Badillo Rivera KM, Sandoval K, Villanueva Dávalos V,
 Enriquez Lencinas LE, Mendoza-Revilla J, Adhikari K, González-Buenfil R, Chen
 JW, Zhang ET, et al. Clotting factor genes are associated with preeclampsia in
 high-altitude pregnant women in the Peruvian Andes. *Am. J. Hum. Genet.* 2022;109:1117–1139.
- Liu X, White S, Peng B, Johnson AD, Brody JA, Li AH, Huang Z, Carroll A, Wei P,
 Gibbs R, et al. WGSA: an annotation pipeline for human genome sequencing
 studies. J. Med. Genet. 2016;53:111–112.
- Løset M, Johnson MP, Melton PE, Ang W, Huang R-C, Mori TA, Beilin LJ, Pennell
 C, Roten LT, Iversen A-C, et al. Preeclampsia and cardiovascular disease share
 genetic risk factors on chromosome 2q22. Pregnancy Hypertens. Int. J. Womens
 Cardiovasc. Health. 2014;4:178–185.
- LaMarca B. Endothelial dysfunction; an important mediator in the Pathophysiology of Hypertension during Preeclampsia. *Minerva Ginecol.* 2012;64:309–320.
- 53. Trivett C, Lees ZJ, Freeman DJ. Adipose tissue function in healthy pregnancy, gestational diabetes mellitus and pre-eclampsia. *Eur. J. Clin. Nutr.* 2021;75:1745–1756.
- 54. Staff AC. The two-stage placental model of preeclampsia: An update. *J. Reprod. Immunol.* 2019;134–135:1–10.
- 55. Li X, Tan H, Huang X, Zhou S, Hu S, Wang X, Xu X, Liu Q, Wen SW. Similarities and differences between the risk factors for gestational hypertension and preeclampsia: A population based cohort study in south China. *Pregnancy Hypertens.* 2016;6:66–71.
- Tyrmi JS, Kaartokallio T, Lokki AI, Jääskeläinen T, Kortelainen E, Ruotsalainen S, Karjalainen J, Ripatti S, Kivioja A, Laisk T, et al. Genetic risk factors associated with preeclampsia and hypertensive disorders of pregnancy. *JAMA Cardiol.* 2023;8:674–683.
- 709 57. Nurkkala J, Kauko A, FinnGen, Laivuori H, Saarela T, Tyrmi JS, Vaura F, Cheng S, Bello NA, Aittokallio J, et al. Associations of polygenic risk scores for

- preeclampsia and blood pressure with hypertensive disorders of pregnancy. *J. Hypertens.* 2023;41:380.
- 58. gatk4-genome-processing-pipeline [Internet]. 2022 [cited 2022 Sep 6]; Available from: https://github.com/gatk-workflows/gatk4-genome-processing-pipeline
- 59. Auwera GAV der, O'Connor BD. Genomics in the cloud: Using Docker, GATK, and WDL in Terra. O'Reilly Media, Inc.; 2020.
- 60. Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM [Internet]. 2013 [cited 2022 Sep 6]; Available from: http://arxiv.org/abs/1303.3997
- 61. Picard Tools By Broad Institute [Internet]. [cited 2022 Sep 6]; Available from: https://broadinstitute.github.io/picard/
- 62. applybqsr Clara Parabricks v3.7 documentation [Internet]. [cited 2022 Sep 6]; Available from:

 https://docs.pyidia.com/clara/parabricks/3.7.0/Documentation/ToolDocs/man
- https://docs.nvidia.com/clara/parabricks/3.7.0/Documentation/ToolDocs/man_appl ybqsr.html
- 726 63. DeepVariant [Internet]. 2022 [cited 2022 Sep 6]; Available from: 727 https://github.com/google/deepvariant
- 64. Liu X, White S, Peng B, Johnson AD, Brody JA, Li AH, Huang Z, Carroll A, Wei P, Gibbs R, et al. WGSA: an annotation pipeline for human genome sequencing studies. *J. Med. Genet.* 2016;53:111–112.
- 65. Aken BL, Ayling S, Barrell D, Clarke L, Curwen V, Fairley S, Fernandez Banet J,
 Billis K, García Girón C, Hourlier T, et al. The Ensembl gene annotation system.
 Database J. Biol. Databases Curation. 2016;2016:baw093.
- 66. Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen W-M. Robust relationship inference in genome-wide association studies. *Bioinformatics*. 2010;26:2867–2873.
- 67. Population Structure and Relatedness Inference using the GENESIS Package
 [Internet]. [cited 2021 Feb 28]; Available from:
 https://www.bioconductor.org/packages/devel/bioc/vignettes/GENESIS/inst/doc/pcair.html
- 68. Conomos MP, Miller MB, Thornton TA. Robust inference of population structure for ancestry prediction and correction of stratification in the presence of relatedness. *Genet. Epidemiol.* 2015;39:276–293.
- 744 69. Zheng X, Levine D, Shen J, Gogarten SM, Laurie C, Weir BS. A high-performance 745 computing toolset for relatedness and principal component analysis of SNP data. 746 *Bioinformatics*. 2012;28:3326–3328.

- 70. Delaneau O, Zagury J-F, Robinson MR, Marchini JL, Dermitzakis ET. Accurate, scalable and integrative haplotype estimation. *Nat. Commun.* 2019;10:5436.
- 71. Maples BK, Gravel S, Kenny EE, Bustamante CD. RFMix: a discriminative modeling approach for rapid and robust local-ancestry inference. *Am. J. Hum. Genet.* 2013;93:278–288.
- 72. Byrska-Bishop M, Evani US, Zhao X, Basile AO, Abel HJ, Regier AA, Corvelo A, Clarke WE, Musunuri R, Nagulapalli K, et al. High-coverage whole-genome sequencing of the expanded 1000 Genomes Project cohort including 602 trios. *Cell.* 2022;185:3426-3440.e19.
- 73. IGSR | samples [Internet]. [cited 2022 May 9]; Available from: https://www.internationalgenome.org/data-portal/sample
- 74. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A, Vukcevic D, Delaneau O, O'Connell J, et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature*. 2018;562:203–209.
- 75.: Category 100319 [Internet]. [cited 2022 Sep 9]; Available from: https://biobank.ndph.ox.ac.uk/ukb/label.cgi?id=100319
- 763 76.: Resource 1671 [Internet]. [cited 2022 Sep 9]; Available from: https://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=1671
- 765 77. : Return 2442 [Internet]. [cited 2023 Jul 19]; Available from: https://biobank.ndph.ox.ac.uk/ukb/dset.cgi?id=2442
- 767 78. Quality Control (QC) | Pan UKBB [Internet]. [cited 2021 Apr 9]; Available from: https://pan-dev.ukbb.broadinstitute.org/docs/qc
- 79. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation
 PLINK: rising to the challenge of larger and richer datasets. *GigaScience* [Internet]. 2015 [cited 2021 Aug 30];4. Available from:
 https://doi.org/10.1186/s13742-015-0047-8
- 773 80. Yang J, Ferreira T, Morris AP, Medland SE, Genetic Investigation of ANthropometric 774 Traits (GIANT) Consortium, DIAbetes Genetics Replication And Meta-analysis 775 (DIAGRAM) Consortium, Madden PAF, Heath AC, Martin NG, Montgomery GW, 776 et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics 777 identifies additional variants influencing complex traits. *Nat. Genet.* 2012;44:369– 778 375, S1-3.
- 779 81. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics*. 2010;26:2190–2191.

- 781 82. Durinck S, Moreau Y, Kasprzyk A, Davis S, De Moor B, Brazma A, Huber W.
 782 BioMart and Bioconductor: a powerful link between biological databases and
 783 microarray data analysis. *Bioinforma. Oxf. Engl.* 2005;21:3439–3440.
- 83. Durinck S, Spellman PT, Birney E, Huber W. Mapping identifiers for the integration
 of genomic datasets with the R/Bioconductor package biomaRt. *Nat. Protoc.* 2009;4:1184–1191.
- 84. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS data. *PLoS Comput. Biol.* 2015;11:e1004219.
- 789 85. Zhang S. A simplified protocol for performing MAGMA/H-MAGMA gene set analysis 790 utilizing high-performance computing environments. *STAR Protoc.* 791 2022;3:101083.
- 792 86. Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. The 793 Molecular Signatures Database (MSigDB) hallmark gene set collection. *Cell Syst.* 794 2015;1:417–425.
- 795 87. Kanehisa M, Goto S. KEGG: Kyoto Encyclopedia of Genes and Genomes. *Nucleic Acids Res.* 2000;28:27–30.
- 797 88. Kanehisa M, Furumichi M, Sato Y, Ishiguro-Watanabe M, Tanabe M. KEGG: 798 integrating viruses and cellular organisms. *Nucleic Acids Res.* 2021;49:D545– 799 D551.
- 800 89. Kauko A, Aittokallio J, Vaura F, Ji H, Ebinger JE, Niiranen T, Cheng S. Sex 801 differences in genetic risk for hypertension. *Hypertension*. 2021;78:1153–1155.
- 90. Honigberg MC, Truong B, Khan RR, Xiao B, Bhatta L, Vy HMT, Guerrero RF,
 Schuermans A, Selvaraj MS, Patel AP, et al. Polygenic prediction of preeclampsia and gestational hypertension. *Nat. Med.* 2023;29:1540–1549.

806

807

808

809

810

811

812

815 Tables

medRxiv preprint doi: https://doi.org/10.110 (which was not certified by peer review	v) is the author/funder, who has	s granted medRxiv a license to	display the preprint in perpe	nis preprint tuity.	
This article is a US Governr	nent work. It is not subject to co Study ரி வளறிசா a C	ppyright under 17 USC 105 and CC0 license Cases	l is also made available Controls	33 ^P value	
PEGS	n = 1,771	n = 202	n = 1,569		
Hypertensive Disorders of Pregnancy, n (%)					
Gestational hypertension	202 (11.4)	202 (100.0)	0 (0.0)	<0.001*	
Number of pregnancies with gestational hypertension					
1	97 (5.5)	97 (48.0)	0 (0.0)		
2	24 (1.4)	24 (11.9)	0 (0.0)	.0.004*	
3 or more	14 (0.9)	14 (6.9)	0 (0.0)	<0.001*	
Missing	1636 (92.4)	67 (33.2)	1569 (100.0)		
Gestational hypertension without preeclampsia	78 (4.4)	78 (38.6)	0 (0.0)	<0.001*	
Preeclampsia	71 (4.0)	71 (35.2)	0 (0.0)		
Number of pregnancies with preeclampsia complication					
1	58 (3.3)	58 (28.7)	0 (0.0)		
2	4 (0.2)	4 (2.0)	0 (0.0)	<0.001*	
3 or more	5 (0.3)	5 (2.5)	0 (0.0)		
Missing	1704 (96.2)	135 (66.8)	1569 (100.0)		
Gestational hypertension and/or preeclampsia	202 (11.4)	202 (100.0)	0 (0.0)	<0.001*	
Covariates					
Age at enrollment, mean (SD) BMI at enrollment, median	47.2 (13.6)	44.8 (12.7)	47.5 (13.7)	0.0071†	
(IQR)	27.4 (23.4, 32.6)	28.7 (25.0, 34.9)	27.3 (23.2, 32.3)	<0.001‡	
Gravidity, median (IQR) Race/ethnicity, n(%)	3.0 (2.0, 4.0)	4.0 (3.0, 5.0)	3.0 (2.0, 4.0)	<0.001‡	
American Indian/Alaskan Native	16 (0.9)	1 (0.5)	15 (1.0)		
Asian	39 (2.2)	3 (1.5)	36 (2.3)		
Black	358 (20.2)	45 (22.3)	313 (20.0)		
Hispanic/Latino	47 (2.7)	3 (1.5)	44 (2.8)	0.1878*	
White	1256 (70.9)	138 (68.3)	1118 (71.3)		
Other (Multiple or Native Hawaiian/Pacific Islander)	22 (1.2)	5 (2.5)	17 (1.1)		
Unknown	33 (1.9)	7 (3.5)	26 (1.7)		

2	1
٠,	4

Predominant genetic similarity group African Admixed American East Asian European South Asian No group	382 (21.6) 8 (0.5) 25 (1.4) 1328 (75.0) 15 (0.8) 13 (0.7)	49 (24.3) 0 (0.0) 1 (0.5) 150 (74.3) 2 (1.0) 0 (0.0)	333 (21.2) 8 (0.5) 24 (1.5) 1178 (75.1) 13 (0.8) 13 (0.8)	0.4288*
Socioeconomic Characteristics, n (%) Educational Level at Enrollment High school education or less Some college or technical/vocational school Bachelor's degree Graduate or professional degree Missing	183 (10.3) 549 (31.0) 530 (29.9) 495 (28.0) 14 (0.8)	14 (6.9) 73 (36.1) 57 (28.2) 57 (28.2) 1 (0.5)	169 (10.8) 476 (30.3) 473 (30.2) 438 (27.9) 13 (0.8)	0.2900*
Income at Enrolment (USD) Less than \$50,000 \$50,000 - \$79,999 \$80,000 or more Missing	659 (37.2) 441 (24.9) 603 (34.0) 68 (3.8)	69 (34.2) 62 (30.7) 66 (32.7) 5 (2.5)	590 (37.6) 379 (24.2) 537 (34.2) 63 (4.0)	0.1810*

Table 1. Demographic characteristics of participants in the PEGS discovery cohort.

^{*} The *P* values were computed by Fisher's exact test.

[†] The P value was computed by t-test.

[‡] The P values were computed by performing the Mann-Whitney U test.

						Multi-ancest 02 cases/1,56	Joint analysis in GWAS		
Nearest			Effect Allele/		(2)	02 08363/1,30	59 CONTROIS)	III GWAG	
Gene	Lead Variant	Chr:Position	Other Allele	EAF	OR	95% CI	P	Р	
LRP1B	rs114954125	2:139978665	G/A	0.051	3.03	2.05-4.49	3.19E-08	3.79E-08	
RARB	rs61176331	3:24930847	A/C	0.048	3.09	2.11-4.53	7.97E-09	9.56E-09	
				Genetic Similarity Group for African Descent					
					(49 cases/333	controls)		
Nearest			Effect Allele/						
Gene	Lead Variant	Chr:Position	Other Allele	EAF	OR	95% CI	P		
RARB	rs61176331	3:24930847	A/C	0.042	6.98	2.97-16.42	8.32E-06		
				Genetic Similarity Group for European Descent					
					(150 cases/1,178 controls)				
Nearest			Effect Allele/						
Gene	Lead Variant	Chr:Position	Other Allele	EAF	OR	95% CI	Р		
LRP1B	rs114954125	2:139978665	G/A	0.067	2.95	1.97-4.42	1.47E-07		
RARB	rs61176331	3:24930847	A/C	0.051	2.37	1.51-3.74	1.92E-04		

Validation

(1,319 cases/2,050 controls)

Nearest		Effect Allele/					
Gene	Lead Variant	Chr:Position	Other Allele	EAF	OR	95% CI	Р
LRP1B	rs114954125	2:139978665	G/A	0.061	1.02	0.83-1.27	8.34E-01
RARB	rs61176331	3:24930847	A/C	0.045	1.29	1.02-1.65	3.73E-02
			GWAS + Validation				

(1,521 cases/3,619 controls)

Nearest			Effect Allele/				
Gene	Lead Variant	Chr:Position	Other Allele	EAF	OR	95% CI	Р
LRP1B	rs114954125	2:139978665	G/A	0.059	1.31	1.09-1.58	4.64E-03
RARB	rs61176331	3:24930847	A/C	0.046	1.66	1.35-2.04	1.27E-06

Table 2. Summary statistics for rs114954125 (*LRP1B*) and rs61176331 (*RARB*). Chr = chromosome, EAF = effect allele frequency

Figures with Figure Legends




Figure 1. Manhattan plot of hypertensive disorders of pregnancy GWAS results and LocusZoom plots of genome-wide significant loci in the PEGS cohort (202 cases and 1,569 controls). The genome coordinates for **B** and **C** reflect GRCh38 assembly.








Figure 2. Manhattan plot of gene-based association analysis of hypertensive disorders of pregnancy. Labeled genes represent the nearest gene within 50 kb upstream or downstream of the gene.




Figure 3. Gene-set analysis using KEGG with MAGMA. The ten most significant KEGG sets are shown on the y-axis. Corresponding unadjusted -log₁₀(p-values) are shown on the x-axis. *P* values were estimated by linear regression model-based testing using MAGMA.




Figure 4. Polygenic score summary statistics and forest plot for odds ratio (ORs) per standard deviation (SD) for hypertensive disorders of pregnancy in multi-ancestry models and African and European genetic similarity groups. AUC: area under the curve